Skip to main content

Reposicionamiento de afatinib para HNSCC en pacientes con anemia de Fanconi

ICI22/00076

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Transferencia de Conocimiento
Call Proyectos de Investigación Clínica Independiente
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prognostic significance of mutation type and chromosome fragility in Fanconi anemia

  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Persico, Ilaria
  • Cavero, Debora|||0000-0002-8912-1890
  • de la Cal, Aurora
  • Río, Paula
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Casado, José A.|||0000-0003-2479-1508
  • Bailador, Almudena
  • Sanchez de la Fuente, Antonio
  • López de Heredia, Miguel|||0000-0003-2826-9565
  • Almazán Castro, Francisco|||0000-0001-6894-9376
  • Antelo, Maria Luisa|||0000-0002-4280-4432
  • Argilés, Bienvenida
  • Badell Serra, Isabel|||0000-0001-6546-2175
  • Baragaño, Marta|||0000-0002-4041-2021
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Bermúdez, Mar
  • Bernués, Marta
  • Buedo Rubio, María Isabel|||0000-0002-2967-1647
  • Carrasco, Estela|||0000-0003-1964-7675
  • Català, Albert|||0000-0003-0133-1752
  • Costa, Dolors|||0000-0002-8276-3292
  • Cuesta, Isabel
  • Fernandez-Delgado, Rafael
  • Fernandez-Teijeiro, Ana|||0000-0002-2359-9330
  • Figuera, Ángela
  • García, Marta|||0000-0001-5155-4730
  • Gondra, Ainhoa
  • González Cruz, Macarena
  • González Muñiz, Soledad
  • Hernandez-Rodriguez, Inés|||0000-0003-2550-9041
  • Ibañez, Fátima
  • Kelleher, Nicholas John
  • Lendínez, Francisco
  • Lopez Rodriguez, Monica|||0000-0001-8134-9682
  • López-Almaraz, Ricardo
  • Marchante, Inmaculada
  • Mendoza, Carmen
  • Nieto, José
  • Ojeda, Emilio
  • Payán-Pernía, Salvador|||0000-0002-4288-7362
  • Peláez, Irene
  • Pérez de Soto, Inmaculada
  • Portugal, Raquel|||0000-0002-7144-9409
  • Ramos-Arroyo, María A.|||0000-0002-7171-9202
  • Regueiro, Alexandra
  • Rodríguez, Ana
  • Rosell, Jordi
  • Saez, Raquel
  • Sánchez, José
  • Sánchez, Martha
  • Senent, Maria Leonor
  • Tapia, María
  • Trujillo-Quintero, Juan Pablo|||0000-0001-5901-9388
  • Vagace Valero, José Manuel|||0000-0001-8751-4319
  • Verdú-Amorós, Jaime|||0000-0002-0900-0889
  • Verdugo, Victória
  • Vidales, Isabel
  • Villarreal, Jasson
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Sevilla, Julián|||0000-0002-6852-1860
  • Bueren, Juan|||0000-0002-3228-7013
  • Surralles, Jordi|||0000-0002-4041-7519
Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk and prognostic factors, and develop novel therapeutic strategies, the Spanish Registry of Patients with FA collects data on clinical features, chromosome fragility, genetic subtypes, and DNA sequencing with informed consent of participating individuals. In this article, we describe the clinical evolution of 227 patients followed up for up to 30 years, for whom our data indicate a cumulative cancer incidence of 86% by age 50. We found that patients with lower chromosome fragility had a milder malformation spectrum and better outcomes in terms of later-onset hematologic impairment, less severe bone marrow failure, and lower cancer risk. We also found that outcomes were better for patients with mutations leading to mutant FANCA protein expression (genetic hypomorphism) than for patients lacking this protein. Likewise, prognosis was consistently better for patients with biallelic mutations in FANCD2 (mainly hypomorphic mutations) than for patients with biallelic mutations in FANCA and FANCG, with the lack of the mutant protein in patients with biallelic mutations in FANCG contributing to their poorer outcomes. Our results regarding the clinical impact of chromosome fragility and genetic hypomorphism suggest that mutant FA proteins retain residual activity. This finding should encourage the development of novel therapeutic strategies aimed at partially or fully enhancing mutant FA function, thereby preventing or delaying bone marrow failure and cancer in patients with FA. Clinical Trial Registration number: NCT06490510.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting protein-protein interactions in drug discovery, Modulators approved or in clinical trials for cancer treatment

  • Camps-Fajol, Cristina
  • Cavero, Debora|||0000-0002-8912-1890
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Surralles, Jordi|||0000-0002-4041-7519
Protein-protein interactions (PPIs) form complex cellular networks fundamental to many key biological processes, including signal transduction, cell proliferation and DNA repair. In consequence, their perturbation is often associated with many human diseases. Targeting PPIs offers a promising approach in drug discovery and ongoing advancements in this field hold the potential to provide highly specific therapies for a wide range of complex diseases. Despite the development of PPI modulators is challenging, advances in the genetic, proteomic and computational level have facilitated their discovery and optimization. Focusing on anticancer drugs, in the last years several PPI modulators have entered clinical trials and venetoclax, which targets Bcl-2 family proteins, has been approved for treating different types of leukemia. This review discusses the clinical development status of drugs modulating several PPIs, such as MDM2-4/p53, Hsp90/Hsp90, Hsp90/CDC37, c-Myc/Max, KRAS/SOS1, CCR5/CCL5, CCR2/CCL2 or Smac/XIAP, in cancer drug discovery.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma

  • Anguera, Georgia|||0000-0002-6060-1110
  • Gallego Rubio, Oscar|||0000-0001-5665-0967
  • Llobet, Mireia
  • Berga, Núria|||0009-0002-1488-8998
  • Moreno Martinez, Maria Estela|||0000-0001-6752-873X
  • Leon, Xavier
  • Kratz, Christian
  • Garcia-Escudero, Ramon|||0000-0001-5640-6542
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Surralles, Jordi|||0000-0002-4041-7519
Individuals diagnosed with Fanconi anemia (FA) present an incidence of 500- to 700-fold higher to develop head and neck squamous carcinomas (HNSCCs) compared to the general population. Effective anticancer treatments for FA-HNSCCs are missing. Several studies demonstrated that FA-HNSCCs overexpress the epithelial growth factor receptor (EGFR) and their viability is highly dependent on this pathway, as FA-HNSCCs cells are highly sensitive to EGFR inhibitors such as afatinib in preclinical models, which led to an orphan drug designation by EMA in 2018. The AFAN trial is a phase Ib/II, single arm, non-randomized, open-label, multicenter study to determine whether afatinib is effective and safe in patients with FA and advanced / metastatic HNSCC. Patients could be treatment-naïve or progressed to a previous systemic treatment with immunotherapy, chemotherapy or cetuximab. Afatinib will be administered orally at a starting dose of 20 mg /day (weeks 1-2), escalating to 30 mg / day at weeks 3-4 and to 40 mg / day thereafter provided no adverse events occur. Treatment will be maintained until disease progression / secondary primary tumor, loss to follow-up, unacceptable toxicity, patient withdrawal or death. Dose reductions and delays will be allowed. All patients will undergo periodic tumor assessments by CT or MRI scan every 12 weeks (3 months) from the start of the study treatment until progression / SPT or patient withdrawal. The primary endpoint is objective response rate (ORR) after 9 months of study treatment initiation according to RECIST V1.1. Secondary endpoints include disease control rate, duration of response, disease-free survival, overall survival, safety, patient reported outcomes and ancillary studies. The expected sample size is 25 patients calculated using a Simon II stage design (α = 0.1; β = 80%), taking as null hypothesis a 9-month ORR of 20% and an alternative ORR of 40%. The AFAN trial will investigate if afatinib is an effective treatment in FA patients with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx.